Tuberculosis continues to kill over a million people annually despite decades of BCG vaccination, largely because BCG — administered systemically — never adequately arms the lung mucosa, the primary battlefield of Mycobacterium tuberculosis infection. A novel delivery strategy that targets mucosal immunity directly at the respiratory site of infection could meaningfully shift that calculus, making this preclinical work relevant to a global unmet need.
The candidate platform, designated TB-PCF, engineers a fusion protein pairing two well-characterized M. tuberculosis antigens — ESAT6 and CFP10 — with Cholera Toxin B subunit (CTB) as a mucosal adjuvant and an IgG-Fc domain designed to promote polymerization and antigen uptake by professional antigen-presenting cells. In a prime-boost mouse model — systemic priming followed by intranasal or mucosal boosting — TB-PCF generated antigen-specific IgG and IgA in both serum and bronchoalveolar lavage fluid, alongside polyfunctional Th1/Th17 systemic responses marked by elevated IFN-γ and IL-17. Most strikingly, splenocytes from TB-PCF-vaccinated animals outperformed BCG-derived cells in a mycobacterial growth inhibition assay in vitro. However, when animals faced live M. tuberculosis challenge, only BCG produced a statistically significant reduction in lung bacterial burden — TB-PCF did not.
This disconnect between robust in vitro killing and absent in vivo protection is scientifically instructive rather than merely disappointing. It reinforces longstanding concerns in TB vaccinology that functional immunogenicity assays do not reliably predict sterilizing protection — a problem that has plagued the field through multiple failed efficacy trials in humans. The ESAT6-CFP10 antigen pairing, while immunodominant and diagnostically useful, may represent too narrow an antigenic target for durable protection, potentially because M. tuberculosis can modulate or evade immunity to these specific epitopes. The platform architecture — CTB fusion plus Fc-mediated polymerization — nonetheless represents a technically sophisticated mucosal delivery chassis worth retaining as antigen combinations are iteratively screened. As a purely mouse-based, single-institution study without challenge dose standardization disclosed in the excerpt, conclusions remain early-stage. This is incremental but directionally valuable: the delivery scaffold advances, while antigen selection emerges as the rate-limiting variable.